Evidence map›Paper›PMID 27393374›Full record

ArticleJournal of neurochemistry2016

Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter.

Molly M McGinnis, Cody A Siciliano, Sara R Jones

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. ESG-1-60 and ESG-1-61: Novel dopamine DBritish journal of pharmacology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Dopamine transporter function fluctuates across sleep/wake state: potential impact for addiction.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  13. Article
  14. (±)VK4-40, a novel dopamine DBritish journal of pharmacology · 2020
    Article
  15. Newly Developed Dopamine DThe Journal of pharmacology and experimental therapeutics · 2019
    Article
  16. Article
  17. Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
  18. Selective DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Molly M McGinnisDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0003-0173-3380
Cody A SicilianoDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Sara R JonesDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. srjones@wakehealth.edu.

Funding

TROPANE EVALUATION AND GENERAL SCIENTIFIC SERVICES COREP50DA006634 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI NADER, MICHAEL A · 1991 to 2019
$30.8M
MULTI-DISCIPLINARY TRAINING IN THE BIOLOGY OF ALCOHOLISMT32AA007565 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BRIAN A MCCOOL · 1994 to 2026
$10.1M
A Novel Animal Model of Cocaine AddictionR01DA014030 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2001 to 2015
$3.2M
Dopamine Transporter Changes Following Cocaine Self-AdministrationR01DA021325 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2007 to 2011
$1.4M
Methylphenidate, Serotonin and Dopamine InteractionsR01DA030161 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2010 to 2014
$1.4M
Amphetamine administration during a rodent model of cocaine abuseF31DA037710 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SICILIANO, CODY · 2015 to 2015
$38k
NIAAA NIH HHS T32 AA007565NIDA NIH HHS F31 DA037710NIDA NIH HHS P50 DA006634NIDA NIH HHS R01 DA014030NIDA NIH HHS R01 DA021325NIDA NIH HHS R01 DA030161
6 · The paper itself

Abstract

Cocaine is a commonly abused central nervous system stimulant that enhances dopamine (DA) neurotransmission through its ability to block dopamine transporters (DATs). Recent evidence suggests there may be an interaction between DATs and D2/D3 autoreceptors that modulates cocaine's effects. The purpose of this study was to explore how D2/D3 autoreceptors modulate the ability of cocaine to inhibit DA uptake through DATs on pre-synaptic DA terminals. Using fast-scan cyclic voltammetry in brain slices containing the nucleus accumbens core from male and female C57BL/6J mice, we first sought to examine the effects of global autoreceptor blockade using the non-selective D2/D3 autoreceptor antagonist, raclopride. We found that the ability of cocaine to inhibit DA uptake was increased by raclopride and that this effect was consistent across sexes. Furthermore, using D2 (L-741,626) or D3 (SB-277011-A) autoreceptor selective antagonists, we discovered that blockade of D3, but not D2, autoreceptors was responsible for the increased cocaine potency. Alterations in cocaine potency were attributable to alterations in uptake inhibition, rather than cocaine effects on vesicular DA release, suggesting that these results may be a product of a functional D3/DAT interaction apart from the canonical inhibitory actions of D3 autoreceptors on DA release. In addition, application of D2 (sumanirole) and D3 (PD 128907) autoreceptor-specific agonists had inverse effects, whereby D2 autoreceptor activation decreased cocaine potency and D3 autoreceptor activation had no effect. Together, these data show that DA autoreceptors dynamically regulate cocaine potency at the DAT, which is important for understanding cocaine's rewarding and addictive properties. We propose a model whereby presynaptic dopamine autoreceptors dynamically modulate cocaine potency through two separate mechanisms. We demonstrate that D2 agonists decrease cocaine potency, whereas D3 antagonists increase cocaine potency, likely through an allosteric mechanism outside of their canonical actions on dopamine release. These findings give important and novel insight into the contribution of D2/D3 autoreceptors to dopamine transporter function.

Indexed as

AnimalsAutoreceptorsCocaineDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsDrug SynergismFemaleIndolesMaleMiceMice, Inbred C57BLNitrilesPiperidinesRacloprideReceptors, Dopamine D23-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indoleAutoreceptorsCocaineDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsDRD2 protein, mouseIndolesNitrilesPiperidinesRacloprideReceptors, Dopamine D2Receptors, Tumor Necrosis Factor, Member 25SB 277011TetrahydroisoquinolinesTnfrsf25 protein, mouseaddictionD2 autoreceptormousenucleus accumbenssex differencesvoltammetry

Identifiers

PMID27393374
PMCPMC5017912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.